Literature DB >> 11070080

MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins.

E Kobet1, X Zeng, Y Zhu, D Keller, H Lu.   

Abstract

p300 acetylates and activates the tumor suppressor p53 after DNA damage. Here, we show that MDM2, a negative-feedback regulator of p53, inhibited p300-mediated p53 acetylation by complexing with these two proteins. First, we purified a p300-MDM2-p53 protein complex from HeLa nuclear extracts, which was inactive in p53 acetylation, but active in histone acetylation. Also, wild-type, but not N-terminally deleted, MDM2 inhibited p53 acetylation by p300 in vitro and in vivo. This inhibition was specific for p53, because MDM2 did not affect acetylation of histones or the C terminus of p73 by p300. Consequently, wild-type, but not the mutant, MDM2 repressed the p300-stimulated sequence-specific DNA-binding and transcriptional activities of p53. These results demonstrate that an additional mechanism of p53 inactivation by MDM2 is to inhibit p53 acetylation by p300.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070080      PMCID: PMC18801          DOI: 10.1073/pnas.97.23.12547

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  DNA damage-induced activation of p53 by the checkpoint kinase Chk2.

Authors:  A Hirao; Y Y Kong; S Matsuoka; A Wakeham; J Ruland; H Yoshida; D Liu; S J Elledge; T W Mak
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

2.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

3.  p53 phosphorylation and association with murine double minute 2, c-Jun NH2-terminal kinase, p14ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation.

Authors:  T Buschmann; V Adler; E Matusevich; S Y Fuchs; Z Ronai
Journal:  Cancer Res       Date:  2000-02-15       Impact factor: 12.701

4.  The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis.

Authors:  X Zeng; X Li; A Miller; Z Yuan; W Yuan; R P Kwok; R Goodman; H Lu
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

5.  The p53-mdm-2 autoregulatory feedback loop.

Authors:  X Wu; J H Bayle; D Olson; A J Levine
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

6.  Nucleolar Arf sequesters Mdm2 and activates p53.

Authors:  J D Weber; L J Taylor; M F Roussel; C J Sherr; D Bar-Sagi
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

7.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.

Authors:  S Y Shieh; J Ahn; K Tamai; Y Taya; C Prives
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

8.  Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.

Authors:  N H Chehab; A Malikzay; M Appel; T D Halazonetis
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

Review 9.  MDM2--master regulator of the p53 tumor suppressor protein.

Authors:  J Momand; H H Wu; G Dasgupta
Journal:  Gene       Date:  2000-01-25       Impact factor: 3.688

10.  Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.

Authors:  R Honda; H Yasuda
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

View more
  58 in total

1.  Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation.

Authors:  Jayne M Stommel; Geoffrey M Wahl
Journal:  EMBO J       Date:  2004-03-18       Impact factor: 11.598

2.  MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output.

Authors:  Lihong Chen; Zhenyu Li; Aleksandra K Zwolinska; Matthew A Smith; Brittany Cross; John Koomen; Zhi-Min Yuan; Thomas Jenuwein; Jean-Christophe Marine; Kenneth L Wright; Jiandong Chen
Journal:  EMBO J       Date:  2010-06-29       Impact factor: 11.598

3.  TRIM25 has a dual function in the p53/Mdm2 circuit.

Authors:  P Zhang; S Elabd; S Hammer; V Solozobova; H Yan; F Bartel; S Inoue; T Henrich; J Wittbrodt; F Loosli; G Davidson; C Blattner
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

4.  MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.

Authors:  Chuangui Wang; Alexey Ivanov; Lihong Chen; William J Fredericks; Ed Seto; Frank J Rauscher; Jiandong Chen
Journal:  EMBO J       Date:  2005-08-18       Impact factor: 11.598

5.  Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.

Authors:  Abhik Saha; Masanao Murakami; Pankaj Kumar; Bharat Bajaj; Karen Sims; Erle S Robertson
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

6.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.

Authors:  Josephine C Ferreon; Chul Won Lee; Munehito Arai; Maria A Martinez-Yamout; H Jane Dyson; Peter E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

7.  Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element.

Authors:  Surajit Sinha; Sunil Kumar Malonia; Smriti P K Mittal; Kamini Singh; Sreenath Kadreppa; Rohan Kamat; Robin Mukhopadhyaya; Jayanta K Pal; Samit Chattopadhyay
Journal:  EMBO J       Date:  2010-01-14       Impact factor: 11.598

8.  Structure of the Taz2 domain of p300: insights into ligand binding.

Authors:  Maria Miller; Zbigniew Dauter; Scott Cherry; Joseph E Tropea; Alexander Wlodawer
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-11-17

Review 9.  Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.

Authors:  Tiffany Devine; Mu-Shui Dai
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

10.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.